**REFERENCES**

[1] Mortality Analyses, Johns Hopkins Coronavirus Resource Center. Accessed:

May 11, 2020. [Online]. Available: https://coronavirus.jhu.edu/

data/mortality

[2] Worldometer, Worldometer COVID-19 Pandemic, Worldometer. Accessed:

May 12, 2020. [Online]. Available: https://www.worldometers.

info/coronavirus/?utm\_campaign = homeAdvegas1?%22

[3] C. ¸ Stef˘anescu, I. Petrescu, and A. Munteanu, “Intellectual property in

critical conditions,” in Proc. WSEAS 3rd World Multiconf. Appl. Econ.,

Bus. Develop, WSEAS Press, 2011.

[4] S. Chopra and A. Negi, “Role of intellectual property during recession,”

J. Intell. Property Rights, vol. 15, pp. 122–129, 2010.

[5] B. W. Jacobs, “Using intellectual property to secure financing after the

worst financial crisis since the great depression,” Marqette Intellectual

Property Law Rev., vol. 15, pp. 450–464, 2011.

[6] J. M. Champagne, “Access to essential medicines in developing countries:

the role of international intellectual property law & policy in the access

crisis,” Albany Law J. Sci. Technol., vol. 22, pp. 75–101, 2011.

[7] D. Halbert, “Moralized discourses: South Africa’s intellectual property

fight for access to AIDS drugs,” Seattle J. Social Justice, vol. 1, no. 2,

2002, Art. no. 2.

[8] J. A. Harrelson, “TRIPS, pharmaceutical patents, and the HIV/Aids

crisis: Finding the proper balance between intellectual property rights and

compassion,” in Proc. Widener Law Symp. J., 2001, vol. 7, pp. 175–201.

[9] M. Childs, “Towards a patent pool for HIV medicines: The background,”

Open AIDS J., vol. 4, pp. 33–36, 2010.

[10] K. L. Cox, “The medicines patent pool: Promoting access and innovation

for life-saving medicines through voluntary licenses,” Hastings Sci.

Technol. Law J., vol. 4, no. 2, pp. 293–326, 2012.

[11] A. Krattiger, S. P. Kowalski, R. Eiss, and A. Taubman, “Intellectual

property management strategies to accelerate the development and access

of vaccines and diagnostics: Case studies on pandemic influenza, malaria

and SARS,” pp. 67–134, 2006. [Online]. Available: https://scholars.unh.

edu/law\_facpub/201/

[12] A. Berkman, “The global aids crisis: Human rights, international pharmaceutical

markets and intellectual property,” Connecticut J. Int. Law,

vol. 17, 2001, pp. 149–155.

[13] B. Reiter, “Theory and methodology of exploratory social science research,”

Int. J. Sci. Res. Methodol., vol. 5, no. 4, pp. 129–150, 2017.

[14] Ø. Pålshaugen, “How to generate knowledge from single case research

on innovation?” Int. J. Action Res., vol. 5, no. 3, pp. 231–254, 2009.

[15] M. Barzelay, “The single case study as intellectually ambitious inquiry,”

J. Public Admin. Res. Theory, vol. 3, no. 3, pp. 305–318, 1993.

[16] T.Wang, F. Tietze, and R. Phaal, “Intellectual property strategy development

through roadmapping,” in Proc. R&D Manage. Conf., Milan, Italy,

2018, pp. 1–17.

[17] T. Wang, F. Tietze, R. Phaal, and N. Athanassopoulou, “Roadmapping

for strategic management of intellectual property,” in Proc. R&D Manag.

Conf., Leuven, Belgium, 2017.

[18] WHO, “Coronavirus disease (COVID-2019) R&D,” WHO. Accessed:

Apr. 3, 2020. [Online].Available: http://www.who.int/blueprint/prioritydiseases/

key-action/novel-coronavirus/en/

[19] “Why is Germany able to test for coronavirus so much more than

the UK?” Reaction, (Mar. 31, 2020). Accessed: Apr. 3, 2020. [Online].

Available: https://reaction.life/why-is-germany-able-to-test-forcoronavirus-

so-much-more-than-the-uk/

[20] “Ventilator challenge UK consortium,” Penlon. Accessed: Apr.1,

2020. [Online]. Available: https://www.penlon.com/Blog/March-2020/

Ventilator-Challenge-UK-Consortium

[21] “Cobra biologics is proud to be part of a consortium to rapidly develop

a COVID-19 vaccine. Accessed: Apr. 3, 2020. [Online]. Available:

https://www.outsourcedpharma.com/doc/cobra-biologics-proudto-

be-part-of-a-consortium-rapidly-develop-covid-vaccine-0001

[22] “Towards a drug against COVID-19 | Co-led by Dr. Nir London,

global consortium aims to accelerate drug development,”

WeizmannCompass, (Mar. 30, 2020). Accessed: Apr. 3, 2020.

[Online]. Available: http://www.weizmann.ac.il/WeizmannCompass/

sections/briefs/towards-a-drug-against-covid-19

[23] “Here are some drugs that may be repurposed to treat coronavirus,”

NBC News, Accessed: Apr. 3, 2020. [Online]. Available:

https://www.nbcnews.com/health/health-news/here-are-some-existingdrugs-

may-be-repurposed-treat-coronavirus-n1162021

[24] Clover and GSK announce research collaboration to evaluate

coronavirus (COVID-19) vaccine candidate with pandemic adjuvant

system | GSK. Accessed: Apr. 3, 2020. [Online]. Available:

https://www.gsk.com/en-gb/media/press-releases/clover-and-gskannounce-

research-collaboration-to-evaluate-coronavirus-covid-19-

vaccine-candidate-with-pandemic-adjuvant-system/

[25] N. Media, “Novartis and others in ‘unprecedented’ COVID-19 partnership,”

Life Sci. IP Rev., Accessed: Mar. 30, 2020. [Online]. Available:

https://www.lifesciencesipreview.com/news/novartis-and-othersin-

unprecedented-covid-19-partnership-3971